Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 11/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.50 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | AHCY | P23526 | 3/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050255 | 1.00 | P2RY1 (0.50) | P2RY1P2RY2P2RY11CA5ANT5E | |
| SCHEMBL21050305 | 0.90 | P2RY1 (0.45) | P2RY1P2RY2P2RY11CA5ANT5E | |
| SCHEMBL21050273 | 0.90 | P2RY1 (0.62) | P2RY1P2RY2P2RY11NT5E | |
| SCHEMBL21050226 | 0.90 | P2RY1 (0.62) | P2RY1P2RY2P2RY11NT5E | |
| SCHEMBL21050310 | 0.90 | P2RY1 (0.45) | P2RY1P2RY2P2RY11CA5ANT5E | |
| SCHEMBL21050257 | 0.86 | P2RY1 (0.49) | P2RY1P2RY2P2RY11NT5E | |
| SCHEMBL21050311 | 0.86 | P2RY1 (0.49) | P2RY1P2RY2P2RY11NT5E | |
| SCHEMBL21100303 | 0.86 | P2RY1 (0.52) | P2RY1P2RY2P2RY11CA5ANT5E | |
| SCHEMBL21050275 | 0.85 | POLG (0.50) | P2RY1P2RY2P2RY6 | |
| SCHEMBL21050234 | 0.85 | POLG (0.50) | P2RY1P2RY2P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | claimed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | P2RY1 3371/4885P2RY2 4227/4885P2RY11 3737/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | P2RY1 3371/4885P2RY2 4227/4885P2RY11 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.